Table 1.

Clinical characteristics of patients with infantile spasms and focal seizures treated with vigabatrin.

	Infantile spasms (N=18)	Focal seizures (N=13)	P value
Age of onset (months)	5.4 (1–12)	11 (0–48)	0.046*
Sex (M : F)	8 : 10	8 : 5	1.000†
vigabatrin as first vs second choice	11 : 7	9 : 4	0.011†
Genetic testing	tuberous sclerosis complex 1: 1, tuberous sclerosis complex 2: 5, No mutation identified: 1	tuberous sclerosis complex 2: 1	-
Max. Dose (mg/kg/day)	89 (46–145)	81 (45–125)	0.362*
Response rate**	16/ 18	6/13	0.029†
Presence vs absence of intellectual disability	13 : 5	5 : 8	0.585†

^*Student’s t-test

^†Chi-square test

^**“Response” was defined as the cessation of clinical spasms in patients with infantile spasms and being seizure-free for 1 year in patients with focal seizures